AVC-S-201

About Avidicure

Avidicure is a private, preclinical-stage biotech developing a first-in-class antibody modality designed to deliver three synergistic activation signals to immune cells, a feature lacking in current antibody therapies. The company's proprietary 'Actibody' platform aims to create potent, durable, and safe monotherapies for oncology and autoimmune diseases by fully engaging both innate and adaptive immunity. Backed by top-tier investors including EQT Life Sciences and BioGeneration Ventures, Avidicure is advancing its lead γδ T cell-targeting program for hematologic and solid tumors while leveraging its platform for broad therapeutic potential.

Therapeutic Areas